title: Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model.
abstract: Although chemotherapy remains among the best treatment options for most cancers, adjuvant therapies such as dendritic cell (DC)-based immunotherapy have been added to treatment protocols to destroy residual tumor cells. IFN-gamma secreting T cells specific for survivin was found after temozolomide (TMZ) treatment in C57BL/6 mice intracranial (i.c.) inoculated with GL26 cells. Furthermore, combination treatment with low-dose TMZ (2.5mg/kg/day, i.p.) chemotherapy followed by vaccination with survivin RNA-transfected DCs (1 x 10(6)cells/mouse, s.c.) enhanced T cells responses specific for survivin and improved survival rate compared with DC vaccination alone or TMZ treatment alone in tumor inoculated mice. However, these enhancements of T cells responses by TMZ treatment were not observed in mice without tumor inoculation. These results suggested that cross-priming by TMZ may enhance antitumor immunity of DC vaccination in murine brain tumor model.
authors.affiliation: Department of Neurosurgery, College of Medicine, The Catholic University of Korea, 505 Banpo-dong, Seocho-gu, Seoul 137-701, Republic of Korea.
authors.forename: Sung-Dong
authors.initials: SD
authors.lastname: Park
authors.forename: Chang-Hyun
authors.initials: CH
authors.lastname: Kim
authors.forename: Chung-Kwon
authors.initials: CK
authors.lastname: Kim
authors.forename: Jin-A
authors.initials: JA
authors.lastname: Park
authors.forename: Hyun-Jung
authors.initials: HJ
authors.lastname: Sohn
authors.forename: Yong-Kil
authors.initials: YK
authors.lastname: Hong
authors.forename: Tai-Gyu
authors.initials: TG
authors.lastname: Kim
mesh_terms: D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D001932:Brain Neoplasms / Q000276:immunology / Q000628:therapy*; D045142:Cross-Priming; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000494:pharmacology; D003713:Dendritic Cells / Q000276:immunology*; D004195:Disease Models, Animal; D005260:Female; D051034:Inhibitor of Apoptosis Proteins; D008213:Lymphocyte Activation; D051379:Mice; D008810:Mice, Inbred C57BL; D008869:Microtubule-Associated Proteins / Q000502:physiology; D012097:Repressor Proteins; D000077022:Survivin; D000077204:Temozolomide; D014162:Transfection; D014611:Vaccination
chemical_list: D018906:Antineoplastic Agents, Alkylating; C117749:Birc5 protein, mouse; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D012097:Repressor Proteins; D000077022:Survivin; D003606:Dacarbazine; D000077204:Temozolomide